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The role of nitric oxide in bacillus Calmette-Guerin
mediated anti-tumour effects in human bladder cancer
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Summary Bacillus Calmette-Guthin (BCG) has been used for many years to treat cancer of the urinary bladder. It constitutes effective
intravesical therapy of carcinoma in situ and recurrent superficial bladder cancer. Although the mechanism of action is unknown, most
evidence suggests an immune-mediated mechanism. BCG treatment is known to increase cytokine production in the urinary bladder. As
cytokines may induce nitric oxide synthase (NOS) activity and as nitric oxide (NO) exerts cytotoxic effects on tumourcells, we investigated the
role of NO in BCG-mediated anti-tumour activity. Here we demonstrate a marked induction of both calcium-dependent and calcium-
independent NOS activity in the human urinary bladder after BCG treatment. The presence of NOS in the urothelial cells was also
demonstrated by the use of immunohistochemistry. Furthermore, patients treated with BCG showed a 30 times higher production of gaseous
NO as measured in the urinary bladder by chemiluminescence. Finally, NO donors exerted cytotoxic effects on bladder cancer cell lines.
These findings suggest that NO synthesis may be an important mechanism in BCG-mediated anti-tumour therapy.
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Unnarx bladder cancer is the fourth most frequent form of cancer
among men and the ninth among Women. and 50 500 new- cases and
10 600 deaths were estimated in the United States in 1995 (Wingo et
al. 1995). In the future many of these patients w-iII be treated xxith
bacillus Calmette-Gumrin (BCG). which proxides effective treat-
ment ofrecurrent superficial bladder cancer as well as carcinoma in
situ (Morales et al. 1976: Lamm. 1992). Although the actual mecha-
nism of the BCG-associated anti-tumour activity is unknown. most
ofthe available evidence indicates an immune-mediated mechanism
(Ratliff et al. 1986: Jackson and James. 1994). Several cvtokines.
e.a. interleukins (LL-1. IL-'. IL-6. L-8). tumour necrosis factor
alpha (TNF-a). and interferon gamma dIFN-y). hax-e been identified
in the patients urine after BCG instillations (Ratliff et al. 1986:
Fleischmann et al. 1989: Jackson et al. 1995). Various cvtokines
haxe been shown to induce the sxnthesis of nitric oxide svnthase
(NOS) (Knowles and Moncada. 1994). and induction of NOS
causes sustained release ofnitric oxide (NO). resulting in high local
concentrations that mav mediate cytostatic and cxtotoxic effects
(Hibbs et al. 1990). NO has been implicated in the cytotoxic activity
of macrophages against tumour cells (Hibbs et al. 1990). Indeed.
BCG was one of the first compounds shown to induce NOS-medi-
ated cvtotoXic effects (Hibbs et al. 1990). Interestinglx. the BCG-
mediated tumoricidal effect in a murine ovarian teratocarcinoma
model has been reported to be dependent on NO (Farias-Eisner et al.
1994 . When BCG wxas administered together w-ith the NOS
inhibitor NG-monomethxl-L-arginine (L-NMMA) in this studx. the
tumoricidal effect of BCG wxas abolished. Altogether. this suggests
that NO might be involxved in the anti-tumour effect ofBCG.
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NO is sxnthesized bx a familx of isoenzxmes called NO
sxnthases (Knowles and Moncada. 1994) and it plays a vital role
as a mediator in the vascular. nervous and immune systems
(Moncada and Higgs. 1995S. Three human isoenzvmes have been
characterized and cloned: endothelial. neuronal and inducible
NOS (eNOS. nNOS. and iNOS) respectivelv. The terminology is
based on the type of cell in which they were first found. although
thex were later found in several other cell types (Knowles and
Moncada. 1994). eNOS and nNOS are constitutively expressed
and calcium-dependent. iNOS is independent of free calcium. and
the synthesis of this enzyme is induced by several cxtokines as
well as lipopolysaccharide (LPS).
The aim ofthis study was to in estigate whether NO production
max be involved in BCG-mediated anti-tumour activitv in the
treatment ofhuman bladder cancer. The study wxas approx ed by the
local ethics committee.
MATERIALS AND METHODS
Patients
In eight patients being treated with BCG (Tice. 5 x RIP CFU.
Organon Teknika. Boxtel. The Netherlands) for recurrent superfi-
cial bladder cancer(stage Ta. grade G2. n = 5) or carcinoma in situ
CIS. n = 3.) bladder biopsy specimens were taken during routine
cystoscopy 4 weeks after the last instillation. All patients had
received at least six BCG instillations.
In 12 patients with recurrent papillary bladder cancer (TaG1.
n = 2: TaG2. n = 10). biopsy specimens from the tumour were
taken during cy stoscopv. Ten patients x ith recurrent papillary
bladder cancer (TaG2. n =10) judged to be in remission by
cystoscopy and bladder wash-out cvtologx sen-ed as control
subjects. Biopsy specimens were taken from the normal mucosa
and immediately frozen in liquid nitrogen.
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Table 1 The calcium-dependent and calcium-independent NOS activity (mean ± s.e.m.) in urinary bladder biopsy specimens from normal bladder (n = 10).
bladder tumour (n = 12). and BCG-treated patients (n = 8) measured as picomoles L-[U-'Cjcitrulline formed per minute per gram tissue (wet weight)
Normal bladder wall Bladder tumour BCG-treated bladder
Ca2--dependent NOS activity 38.9 - 4.9' 46.2 - 19.3' 161.4 - 19.7 ..
Ca2--independent NOS activity NS 22.2 + 6.6' 58.4 - 23.7'
Statistical significance was determined using the two-tailed unpaired t-test. 'P < 0.05: '*P < 0.01: -P < 0.001: NS, not significant.
The gaseous NO production in BCG-treated urinary bladders
was measured in five patients with recurrent papillary bladder
cancer (TaG2. n = 3) and carcinoma in situ (CIS. n = 2) four weeks
after the last BCG instillation. Instillations (1 h) of BCG into the
bladder had been performed once monthly for more than 6 months
in all patients. NO measurements were performed immediately
before a treatment. Seven patients undergoing routine cystoscopy
during remission of their bladder tumour (TaG1. n = 1: TaG2. n =
6) served as control subjects. Only patients free of recurrent
cancer. as determined by cystoscopv and bladder wash-out
cvtology. were included. All patients had negative urine cultures.
Assay of NOS
NOS activity wvas measured by the conversion of L-[U-'4C]argi-
nine to L-[U-'4C]citrulline. The frozen tissue (50-250 mg) was
homogenized (IKA Dispersing Tool) in ice-cold buffer (3:1.
.d mg-') containing 320mrm sucrose. 10 mm. Hepes. 0.1 mm
EGTA. 1 mm DL-dithiothreitol. 10 ic ml-' trypsin inhibitor. 10 jg
ml-, leupeptin. phenylmethylsulfonyl fluoride 100 jg ml' and
2 jg ml-' aprotinin (adjusted to pH 7.2 at 20'C with 1 as
hydrochloric acid). The homogenate was centrifuged at 10 000g
for 30 min at 4'C. and the supernatants collected and stored on ice
before use. To measure the NOS activity in the supernatants 20 pA
was added to tubes prewarmed to 3TC. containing 100 jil of a
buffer consisting of50 mmr potassium phosphate. pH 7.2. 50 mM L-
valine. 100 gom NADPH. 1 mM L-Citrulline. 20 jiM L-arginine and
L-[U-'-C]arginine (Amersham. 150 000 d.p.m.). 1.2 mm calcium
chloride. Duplicate incubations for 10 min at 37"C were performed
for each sample in the presence or absence ofeither EGTA (2 n'mI)
or EGTA plus Nw-monomethyl-L-arginine (2 mt each). to deter-
mine the level of the calcium-independent and calcium-indepen-
dent activity respectively. The reaction was terminated by removal
of the substrate and dilution by addition of 1.5 ml of 1:1 (V/V)
water/Dowex AF 50W-X8. pH 7.5. Water (5 ml) was added to the
incubation mix. and 2 ml of the supematant was removed and
examined for the presence ofL-[lT-'4C]citrulline by liquid scintilla-
tion counting. The level ofcitrulline is expressed as pmol pergram
of tissue (wet weight) per min.
NO excretion
The NO excretion in the urinav bladder was measured bv intro-
ducing 100 ml of air (NO < five parts per billion: p.p.b.) into the
urinary bladder during cystoscopy. The air was aspirated into a
syringe after incubation for 5 min and immediately injected into a
chemiluminescence NO analx ser (CLD 700. Eco Physics.
Durnten. Smitzerland) and peak levels of NO were recorded. The
detection limit for NO was 1 p.p.b. and the analx ser was calibrated
at known concentrations of NO in nitrogen. using an electro-
magnetic flow controller (Environics. Middletox n. CT. USA).
Immunohistochemistry
Immunohistochemistry was performed using rabbit polx clonal
antibodies (Transduction Laboratories. Lexington. KY. USA)
raised against endothelial. brain and macrophage NOS. Frozen
tissue was cut in 10-jm sections in a cryostat and thawed on
slides. fixed in 4%7c paraformaldehyde for 5 min. incubated with
antiserum and washed. The sections were then incubated with
fluorescein isothiocyanate-conjugated anti-antibodies. rinsed and
examined under a Nikon fluorescence microscope.
Cell culture
Bladder cancer cell lines T24 (human) and MBT-2 (murine) were
grown in RPMI-1640 supplemented with 10%-l fetal calf serum.
10 mai Hepes. antibiotics and 2 mM L-gylutamine. For cytotoxic
measurements. cells were plated in 24-well tissue culture plates
(Costar. Cambridge. MA. USA) at a cell density of8000 cells ml-'.
The cells were incubated at 37 C for 24 h for attachment. An
aliquot of 30 jl of dissolved NO donor or solvent (control
subjects) was added to the cell medium and. after incubation at
37-C for 24 and 48 h. the DNA content and [jH]thymidine uptake
were measured. Normal urothelial cells were primary cultured
from the renal pelvis or urinary bladder wall as described previ-
ouslv (Cilento et al. 1994). Cells were maintained in serum-free
keratinocyte growth medium (Keratinocvte-SF.M. Life Technolo-
gies). supplemented with antibiotics. cholera toxin (30 ng ml-!).
5 no ml-' epidermal growth factor and 50jg ml-' bovine pituitary
extract. For cell passage. cultures at about 90% confluence were
detached by incubation for 5 min in 0.05% trypsin/l mrm ethylene-
diaminetetracetic acid. For immunolabelling. cultured urothelial
cells were grown in chamber slides (Costar. Cambridge. MA.
USA) until confluence occurred. The cells were then fixed with
100% ice-cold methanol for 10 min and incubated with the
primary antibody at an appropriate dilution (recommended by the
supplier). washed repeatedly with PBS and then counterstained
with rhodamine-labelled anti-mouse IgG. Immunolabelling of
cultured cells revealed that thev were cytokeratin positive. thereby
confirming that they were of epithelial origin. They were also
vimentin positive. The antibodies used were the broadly reacting
cytokeratin antibody AE1/AE3 anti-cv-tokeratin monoclonal
antibody mixture and anti-vimentin antibodies.
DNA content
Cells were detached from the culture plates by exposure to 0.05%'
trypsin in 0.02%7c EDTA for 5 min at room temperature. The cells
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were lNsed bv addition of 0.01%;- Triton X-100. Bisbenzimide
H33258 (Sigma) was added to the suspension at a concentration of
2 jg ml and the fluorescence was measured in a fluorometer
(Hoefer TKO 100). Calfthymus DNA extract (Sigma) with known
concentrations was used to plot a standard curve for DNA concen-
trations. The total DNA concentration was directlx correlated with
the cell densitv. as assessed bv counting cells in a haemocvtometer.
PH]Thymidine uptake
Cells Were pulsed with ['H]thy-midine (1 Ci per well) 2 h before
harvest. At harvest. the medium was discarded. cells were washed
with PBS and the supernatant was discarded. Ice-cold 10%T
trichloroacetic acid (1 ml) >-as added to each well and incubated
for 15 mmn. Following repeated washings with saline phosphate
buffer. the cell pellet >-as extracted with 0.5 ml of 0.1 '1 sodium
hvdroxide. The suspension was dissolved in 5 ml of scintillation
liquid and counted in a beta-counter.
Cell viability
At har est. the medium was removed and saved in centrifuge vials.
The wells were then washed with calcium-free PBS and the super-
natant >-as added to the centrifuge vials. Cells wvere then detached
from the culture >-ells by adding 0.057 trypsin in 0.02%7 EDTA
for 5 min at room temperature. The cells were resuspended in the
centrifuge xials and spun at 1200 r.p.m. for 5 mMin. The supernatant
was discarded and the cells were resuspended in 0.2'7% trxpan blue
(Gibco). Viability was assessed by counting the proportion of
viable cells in a haemocvtometer.
Statistics
The statistical significance of differences between control and
treatment groups was determined using the tw-o-tailed unpaired t-
test. Significance Awas defined as P < 0.05.
RESULTS
NOS activity
Calcium-dependent NOS activity A-as found in the mucosa of
normal urinary bladder biopsy specimens. but no calcium-indepen-
dent activitv was detected (Table 1). Tumour tissues showxed sianifi-
cant calcium-independent NOS activity- and the calcium-dependent
NOS activit- was similar to the activity in normal mucosa (Table 1).
In the mucosaofBCG-treated patients. there >-as a fourfold increase
in calcium-dependent NOS actix it!. as compared with normal
control subjects (Table 1). Patients treated with BCG also showxed a
high calcium-independent NOS activity (Table 1).
Immunohistochemistry of tissue sections
In both normal urothelium (Figure 1A) and tumour tissue (Figure
1B). a marked eNOS-like immunoreactixitv >-as seen in the
urothelial cells. eNOS-like immunoreactivitv- was also found in
BCG-treated bladder mucosa (not shown>. Furthermore. eNOS-
like immunoreactivitxwas evident in the endothelium of blood
vessels (Ficure IC). nNOS-like immunoreactivit) could not be
detected in normal mucosa. tumour tissue or BCG-treated mucosa.
although subepithelial nNOS-like immunoreactivit) >-as detected
in some nerves in the normal bladder (Figure ID). iNOS-like
immunoreactivitx could not be adequately demonstrated as both
the monoclonal and polyclonal iNOS antibodies used showed
staining of the urothelial cells. blood Xessels. neurons and
macrophages. suggesting that the iNOS antibodies were non-
specific and stained all NOS isoenzxmes (not shoxxn).
Direct measurements of gaseous NO in the urinary
bladder in vivo
In BCG-treated patients. the mean NO concentration in the air
aspirated from the bladder was 30 times (450 ± 240 p.p.b. ) higher
than in control subjects ( 15 ± 4 p.p.b.) (Figure 2).
R
Figure 1 Micrographs of human urinary bladders after processing for indirect immunofluorescence. eNOS-like immunoreactvity (arrow) in normal urothelium
(A). tumour tissue (B) and endothelium of blood vessels (C). D nNOS-like immunoreactvity (small arrow) in small nerve fibres in smooth muscle cell bundles in
the normal human bladder. Bar indicates 50 urm
British Journal ofCancer (1998) 78(5). 588-592 C Cancer Research Campaign 1998Nitric oxide andBCG-mediatedanti-tumouractivity 591
A
1401
120 -
_ _ 1loo -
C
O
8
0
cij O-1 cJ r. 80-
C
0 0
: 60
0
40-
Control suects
20 - Figure 2 NO concentrations after 5 rmwn of incubation with air (NO < 5 p.p.b.)
in the urinary badder of five patients treated with BCG and seven untreated
control subjects. All patents had negative urine cultures 0
10 100
SNAP conceratbon (m)
Effect of NO donors on cell viability
A dose-dependent inhibition of [3H]thymidine incorporation and a
reduction in total DNA content were seen when T24 and MBT-2
bladder cancer cell lines were grown in the presence of the NO-
releasing compound S-nitroso-N-acetylpenicillarnine (SNAP
10-1000gm) (Figure 3). There was no significant difference in the
sensitivity of the different cell lines. The same pattern was seen
using sodium nitroprusside (SNP, 0.3-1.5 mM), although a higher
concentration was needed (not shown). The inhibition of cell
growth was found to be partly due to decreased cell viability as
assessed by the trypan blue exclusion method After 24 h of
incubation with 100 PM SNAP, the viable cell count amounted to
70% of that of control subjects (not shown). No reduction in the
DNA concentration was seen when normal urothelial cells were
incubated with SNAP (10-1000 pM) under the same conditions
(Figure 3A). However, inhibition of [3H]thymidine incorporation
was seen when normal urothelial cells were incubated with SNAP
at the highest concentration used (1000 i.m) (Figure 3B).
DISCUSSION
Since the first report of the use of intravesical BCG for the treat-
ment of superficial bladder cancer (Morales et al, 1976), clinical
trials have confirmed that BCG is an effective immunomodulator
that yields superior results to those of chemotherapy (Lamm,
1992). It is now apparent that BCG exerts its effect both directly
on the tumour cells and via the immune system (Jackson and
James, 1994). As an increase in cytokine production has been
demonstrated after BCG instillations (Ratliff et al, 1986;
Fleischmann et al, 1989; Jackson et al, 1995) and cytokines may
cause a sustained release of high concentrations of NO, resulting
in cytostatic and cytotoxic effects on tumour cells (Hibbs et al,
1990), it seemed logical to investigate the possible involvement of
NO in BCG-mediated anti-tumour effects. Interestingly, BCG was
one ofthe first compounds used to induce NOS activity in murine
macrophages when the activated macrophage cytotoxic effect was
studied (Hibbs et al, 1990).
We found a higher degree of both calcium-dependent and
calcium-independent NOS activity in the urinary bladderfollowing
BCG treatment for superficial bladder cancer. The increased
calcium-dependent activity was probably due to an increased
activity ofeNOS, localized to the urothelial cells. Thus, the luminal
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Figure 3 Effect of NO donor addition to cel cultures. The effect on the total
DNA concert (A) and PHithynicine uptake (B) in bladder cancer cell
lines MBT-2 (0) and T24 (0) and normal cultured huom urotflial cells (A)
after 48 h of ikcation with SNAP (10-1000 SUM). Bars represent the mean
s.e.m. for six or more different experiments and are expressed as
percentages of uneated control cells
NO measured in the bladder is probably formed in the urothelium
as NO produced in deeper parts of the submucosa (in subepithelial
nerves) is not likely to reach the lumen as intact NO because ofits
short half-life in biological tissues. The luminal NO is probably
produced by eNOS activity in the urothelium, as judged from our
immunohistochemical findings, although a contribution of iNOS
activity cannot be ruled out. The localization of the calcium-inde-
pendent NOS activity could not be assessed by immunohistochem-
istry, however, because of cross-reactivity of the iNOS antibodies
used with all isoenzymes. It is interesting that the calcium-depen-
dent NOS activity was induced by BCG treatment as calcium-
dependent NOS is usually regarded as being constitutively
expressed, in contrast to the inducible calcium-independent NOS.
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There are. however. reports on cytokine induced calcium-depen-
dent NOS activity in endothelial cells (Rosenkrantz-Weiss. 1994).
It has also been shown that oestrogen increases the calcium-depen-
dent NOS activity in various tissues. including the urinary bladder
(Weiner et al. 1994: Ehren et al. 1995). The mechanism underlving
the increase in calcium-dependent and calcium-independent NOS
activity after BCG treatment is not clear at the present time. Both an
increase in the amount of NOS present and changes in co-factor
concentrations could be possible explanations. as indicated by
previous studies (Rosenkrantz-Weiss. 1994: Weiner et al. 1994).
Although it is clear that NOS activity in the bladders of BCG-
treated patients results in a hiah local concentration ofNO. it is still
not clear whether it is calcium-dependent or calcium-independent
NOS activity that is responsible for the increased production ofNO
in vivo. Thus. in vitro. the calcium-dependent NOS activity domi-
nated over the calcium-independent activity. but this does not
necessarily reflect the actual in -i-o situation.
Significant calcium-independent activity in bladder tumours was
seen. whereas no calcium-independent activitv was detected in the
normal bladder mucosa. Thus. in bladder tumours. both calcium-
dependent and calcium-independent activity was found. This is not
surprising as it has been shown that several tumour cell lines
express NOS (Radomski et al. 1991: Jenkins et al. 1995). and NOS
is also present in human ovarian. uterine and breast cancer
(Thomsen et al. 1994. 1995). However. the role of NO production
in tumour growth is unclear. It has been shown that the NOS
activity in the tumour is correlated with the tumour growth rate
(Jenkins et al. 1995). Furthermore. NO may also be important for
maintaining the blood supply to the turnour by dilatinc the malig-
nant vessels (Andrade et al. 1992). In low concentrations. NO can
stimulate cell growth. whereas high concentrations inhibit cell
growth (Thomae et al. 1995). Thus. NO can be both beneficial and
harmful to tumour growth. Although we do not know the actual
local NO concentration in the bladder wall. our datadefinitely show
a marked increase in the NO concentration after BCG treatment for
bladder cancer. In the present study. we found pronounced
inhibitory effects on cell growth and cell viability when NO donors
were applied to the tumour cell lines. indicating that NO. at high
local concentrations may inhibit tumourgrowth in bladder cancer.
We have presented a new technique for measuring NO produc-
tion in the urinary bladder in vivo. This technique is very inter-
esting as it opens up a minimally invasive possibility ofmeasuring
NO formation directly in patients with bladder cancer. We are now
enaaged in measurements to establish a possible relationship
between NO formation and the response to BCG therapy.
Furthermore. the possibility to enhance the BCG-induced NO
formation by addinm L-arginine will also be investigated as this
may enhance the anti-tumour effect of BCG treatment.
In conclusion. we have demonstrated the presence of NOS
activity in the human urinary bladder. This activity is markedly
enhanced by BCG treatment and large amounts of NO are formed
in the bladder during treatment. NO exerts strong inhibitors effects
on the growth ofbladder cancer cell lines. The present data suggest
that NO may be involved in the anti-tumour activity of BCG.
ACKNOWLEDGEMENTS
This project was supported by the Swedish MRC (project 111l99)i.
Swedish Cancer Society (project 3769-B96-OXAW>. Maud and
British Journal of Cancer (1998) 78(5). 588-592
BrigYer Gustavsson's foundation and the Swedish foundation of
Medical Research.
REFERENCES
Andrade SP. Hart IR and Piper PJ 1992 Inhibitors of nitric oxide sv-nthase
'electiN-elx reduce flo1 in tumour-assc-iated neoxasculature. Br J Pharmacol
107: 129'-1095
Cilento BG. Freeman MR. Schneck FN. Retik AB and Atala A 1994) Phenotypic
and cvtogenic characterization of human bladder urothelia expanded in itro.
J (ril 152: 665-670
Ehren I. Hammarstrom M. Adolfsson J and Wiklund NP 1995 Induction of
calcium-dependent nitric oxide synthase b! sex hormones in the guinea-pig
unnarv bladder. Acta Physiologica Scand 153: 393-394
Fariai-Eisner R. Sherman IP. Aerberhard E and Chaudhuri G 1994iNitric oxide is
an important mediator for tumoricidal activin in vI%o. Proc Natl .4cad Sci US.A
91 9407-9411
Fleischmann JD. TooQSi Z. Ellner JJ. Wernti-orth DB. Ratliff TL and Imbemro AL
1989 Unrinar- interleukins in patients receiving intramesical bacillus Calmette-
Guerin therap- for superficial bladder cancer. Cancer 64: 1447-1454
Hibbs JB Jr. Taintor RR. Vavrin Z Granger DL. Drapier J-C. Amber U and
Lancaster JR Jr) 1990) Snthesis of nitric oxide from a terminal Luanidino
nitrogen atom ofL-arginine: a molecular mechanism regulating cellular
proliferation that targets intracellular iron. In Nitric oxide from L-arvinine: a
bioregularory system: Proceedings ofthe Syvmpohsium on Biological Importance
of.Nirric Oxide. Mooncada S and Higgs A (eds. pp. 189-223. Elsevier:
Amsterdam
Jackson AM and James K 1994 Understandin2 the most successful immunotherapy
for cancer. The Immunoloeist 2: 0 -215
Jackson AM1. Alexandroff AB. Kell\ RW: Skibinska A. Es-taranathan K. Prescott S.
Chisholm GD and James K (199-5 Chancyes in urinarv cvtokines and soluble
intercellular adhesion molecule- 1 ICAM-I in bladder cancer patienus after
bacillus Calmette-Guerin BCG immunotherap!. Clin Ep Immunol 99
369-375
Jenkins DC. Charles IG. Thomsen LL. Moss DW: Holmees LS. Ba! lis SAX. Rhodes P.
e-stmore K. Emson PC and Moncada S 199-5 Roles of nitric oxide in tumor
erovwth Pro.\atl .A-ad Sci US.4 92: 49' 9-4396
Knowles RG and Mioncada S 1994 Nitric oxide sv-nthases in mammals Bicc-hem J
298: 249-258
Lamm DL 199'h Optimal BCG treatment of superficial bladder cancer as defined
bv Amnerican trials.Eur r/212I:12'-16
Moncada S and Hieoes A 1995 M Molecular mechanisms and therapeutic strategies
related to nitric oxide. FASEB J9: 1319-1330
Morales A. Eidinger D and Bruce .AW 1976) Intracavitarn bacillus Calmette-Guefin
in the treatment of superficial bladder tumors.J Lrol 116: 180-183
Radomski MWf Jenkins DC. Holmes L and Moncada S 1991 Human colorectal
adeno<carcinoma cells: differential nitric oxide svnthesis determines their abilit-
to aggregate platelets. Cancer Res 5I: 6073-6078
Ratliff TL. Haaf EO. Catalona WJ 1986 Interleukin-2 production durine
intravesical bacillus Calmette-Guerin therapy for bladder cancer. Clin
Immmunol Immunopathol 40: 375-379
Rosenkrantz-Weiss P. Sessa WC. Milstien S. Kaufman S. Watson CA and Pober JS
1994) Regulation of nitric oxide svnthesis by proinflammator- cytokines in
human umbilical vein endothelial cells. J C/in In est 93: 2236-2243
Thomae KR. Nakavama DK. Billiar TR. Simmons RL. Pitt BR and Davies Pl1995
The effect of nitric oxide on fetal pulnonary arter smooth muscle grow h
JSurz Res 59: 337-343
Thomsen LL. Lawton FG. Knou les RG. Beesle\ JE. Ri eros-fMoreno V and
Moncada S 1994) Nitric oxide svnthase activitv in human evnecoloeical
cancer. Cancer Res 54: 1352-1354
Thomsen LL. Miles DW. Happerfield L Bobrow LG. Know-les RG and Moncada S
(1995 Nitric oxide svrnthase activitv in human breast cancer. Br J Cancer 72:
41-4
Weiner CP. Lizasoain . Bavlis SA. Knowles RG. Charles IG and Moncada S 1994
Induction ofcalcium-dependent nitric oxide sy-nthase b! sex hormones. Prro-
.Natl.Acad Sci USA 91: 5212-5216
Wingo P.A. Tong T and Bolden S 1995 Cancer statistics- Cancer J Clin 45: 8-.0
tCt Cancer Research Campaign 1998